NECLIFE

NECTAR LIFESCIENCES

Small Cap BSE: 532649 NSE: NECLIFE
₹24.45
0.25 (1.03%)
As on 12 August, 2022 | 14:46

Nectar Lifesciences Share Price

Nectar Lifesciences Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Nectar Lifesciences Share Returns

  • Over 1 Month 1.66%
  • Over 3 Month -0.61%
  • Over 6 Month -22.99%
  • Over 1 Year -17.26%

Nectar Lifesciences Key Statistics

P/E Ratio 21.9
PEG Ratio 0.2
Market Cap Cr 548
Price to Book Ratio 0.5
EPS 1.1
Dividend 0
Relative Strength Index 50.78
Money Flow Index 49.77
MACD Signal 0.07
Average True Range 0.87

Nectar Lifesciences Investment Rating

  • Master Rating:
  • Nectar Lifesciences has an operating revenue of Rs. 1,668.85 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 2% needs improvement, ROE of 2% is fair but needs improvement. The company has a reasonable debt to equity of 27%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 24 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Nectar Lifesciences Financials
  • Indicator
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 476
  • 443
  • 365
  • 384
  • 349
  • Operating Expenses Qtr Cr
  • 427
  • 396
  • 337
  • 349
  • 320
  • Operating Profit Qtr Cr
  • 49
  • 47
  • 27
  • 36
  • 29
  • Depreciation Qtr Cr
  • 14
  • 14
  • 14
  • 14
  • 15
  • Interest Qtr Cr
  • 17
  • 18
  • 18
  • 26
  • 26
  • Tax Qtr Cr
  • 6
  • 5
  • -1
  • -1
  • 5
  • Net Profit Qtr Cr
  • 12
  • 10
  • 2
  • 2
  • -41

Nectar Lifesciences Technicals

EMA & SMA

Current Price
24.45
0.25 (1.03%)
  • Bullish Moving Average
  • ___
  • 11
  • Bearish Moving Average
  • ___
  • 5
  • 20 Day
  • 24.16
  • 50 Day
  • 24.4
  • 100 Day
  • 25.24
  • 200 Day
  • 26.96
  • 20 Day
  • 24.26
  • 50 Day
  • 23.89
  • 100 Day
  • 25.59
  • 200 Day
  • 26.97

Nectar Lifesciences Resistance and Support

PIVOT
₹24.22
Resistance
  • First Resistance
  • 24.49
  • Second Resistance
  • 24.77
  • Third Resistance
  • 25.04
Support
  • First Resistance
  • 23.94
  • Second Resistance
  • 23.67
  • Third Resistance
  • 23.39
  • RSI
  • 50.78
  • MFI
  • 49.77
  • MACD Single Line
  • 0.08
  • MACD
  • 0.08

Nectar Lifesciences Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 90,222
  • 6,335,389
  • 70.22
  • Week
  • 114,150
  • 7,457,420
  • 65.33
  • 1 Month
  • 146,266
  • 8,711,603
  • 59.56
  • 6 Month
  • 417,644
  • 19,458,033
  • 46.59

Nectar Lifesciences Result Highlights

Nectar Lifesciences Synopsis

NSE-Medical-Generic Drugs

Nectar Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1541.82 Cr. and Equity Capital is Rs. 22.43 Cr. for the Year ended 31/03/2021. Nectar Lifesciences Ltd. is a Public Limited Listed company incorporated on 27/06/1995 and has its registered office in the State of Punjab, India. Company’s Corporate Identification Number(CIN) is L24232PB1995PLC016664 and registration number is 016664.
  • Market Cap
  • 548
  • Sales
  • 1,668
  • Shares in Float
  • 12.56
  • No of funds
  • 4
  • Yield
  • 0.22
  • Book Value
  • 0.5
  • U/D Vol ratio
  • 1
  • LTDebt / Equity
  • 27
  • Alpha
  • -0.1
  • Beta
  • 1.26

Nectar Lifesciences

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 55.8%
  • 55.8%
  • 55.8%
  • Foreign Portfolio Investors
  • 1.49%
  • 1.67%
  • 1.52%
  • Individual Investors
  • 24.2%
  • 23.83%
  • 23.6%
  • Others
  • 18.51%
  • 18.7%
  • 19.08%

Nectar Lifesciences Management

  • Name
  • Designation
  • Mr. Sanjiv Goyal
  • Chairman & Managing Director
  • Dr. Dinesh Dua
  • Executive Director
  • Mr. Vivek Seth
  • Director
  • Mr. Ajay Swaroop
  • Independent Director
  • Ms. Guljit Sethi
  • Independent Director
  • Dr. Rupinder Tewari
  • Independent Director
  • Ms. Meena Verma
  • Nominee Director
  • Dr. Indu Pal Kaur
  • Independent Director

Nectar Lifesciences Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Nectar Lifesciences Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-13
  • Quarterly Results
  • 2022-05-30
  • Audited Results
  • 2022-02-14
  • Quarterly Results
  • 2021-11-13
  • Quarterly Results
  • 2021-08-14
  • Quarterly Results

Nectar Lifesciences MF Shareholding

  • Name
  • Amount(cr)

Nectar Lifesciences FAQs

What is Share Price of Nectar Lifesciences ?

Nectar Lifesciences share price is ₹24 As on 12 August, 2022 | 14:32

What is the Market Cap of Nectar Lifesciences ?

The Market Cap of Nectar Lifesciences is ₹548.3 Cr As on 12 August, 2022 | 14:32

What is the P/E ratio of Nectar Lifesciences ?

The P/E ratio of Nectar Lifesciences is 21.9 As on 12 August, 2022 | 14:32

What is the PB ratio of Nectar Lifesciences ?

The PB ratio of Nectar Lifesciences is 0.5 As on 12 August, 2022 | 14:32

Q1FY23